Speaker illustration

Doctor Piotr Sobieraj

Medical University of Warsaw, Warsaw (Poland)

Member of:

European Society of Cardiology

Dr Piotr Sobieraj finished his residency training (internal medicine) at Medical University of Warsaw, Department of Internal Medicine, Hypertension and Vascular Diseases and started training in cardiology. His PhD concerned the importance of low diastolic blood pressure in subjects with hypertension. Currently, his scientific research are mainly focused on treatment targets in arterial hypertension, acute pulmonary embolism and echocardiography.

Individualizing the target diastolic blood pressure in patients being treated for hypertension and diabetes

Event: ESC Congress 2021 - The Digital Experience

Topic: Treatment

Session: Diastolic blood pressure: should we care?

Thumbnail

The impact of resting heart rate measured on cardiovascular events in subject with hypertension.

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Epidemiology, Prognosis, Outcome

Session: Hypertension and the J-Curve Phenomenon: Implications for Clinical Practice

Thumbnail

Heart failure events in a clinical trial of arterial hypertension. The acquittal of the SPRINT trial.

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Pharmacotherapy

Session: Hypertension and the Heart

Thumbnail

The association of LEPR rs1137101 polymorphism with the incidence of left ventricular hypertrophy in patients with obstructive sleep apnea and hypertension.

Event: ESC CONGRESS 2019

Topic: Hypertension, Pulmonary Hypertension

Session: Risk factors for cardiovascular disease

Thumbnail

Automated blood pressure measurements: optimal diastolic blood pressure range in treated hypertensives at high cardiovascular risk.

Event: ESC CONGRESS 2019

Topic: Blood Pressure Measurement

Session: Blood pressure measurement

Thumbnail

The effect of on-treatment diastolic blood pressure on the risk of stroke. An investigation using SPRINT trial NHLBI Research Materials.

Event: ESC Congress 2018

Topic: Epidemiology, Prognosis, Outcome

Session: Hypertension and cardiovascular risk

Thumbnail

This platform is supported by

logo Novo Nordisk